利索-全球专利检索

  1. Login
  2. Sign Up

Search Results

51 records (took 0.024 seconds)

    METHODS FOR TREATING HYPERLIPIDEMIA WITH AN ANGPTL8 INHIBITOR AND AN ANGPTL3 INHIBITOR
    1.
    发明申请
    METHODS FOR TREATING HYPERLIPIDEMIA WITH AN ANGPTL8 INHIBITOR AND AN ANGPTL3 INHIBITOR 有权

    公开(公告)号：US20220127348A1

    公开(公告)日：2022-04-28

    申请号：US17571286

    申请日：2022-01-07

    Applicant: Regeneron Pharmaceuticals, Inc.

    Inventor： Jesper GROMADA ,  Viktoria GUSAROVA ,  Andrew J. MURPHY

    IPC: C07K16/22 ,  A61K9/00

    Abstract: The present invention provides methods for treating patients suffering from hyperlipidemia, wherein the patient is non-responsive to, inadequately controlled by, or intolerant to treatment with a standard lipid modifying therapy. The methods of the invention provide for lowering at least one lipid parameter in the patient by administering a therapeutically effective amount of an antibody or antigen-binding fragment thereof that specifically binds to angiopoietin-like protein 8 (ANGPTL8) in combination with a therapeutically effective amount of an antibody that specifically binds to angiopoietin-like protein 3 (ANGPTL3). The combination of an anti-ANGPTL8 antibody with an anti-ANGPTL3 antibody is useful in treating diseases such as hypercholesterolemia, including familial hypercholesterolemia (FH), both heFH and hoFH, as well as hyperlipidemia, hyperlipoproteinemia and dyslipidemia, including hypertriglyceridemia, chylomicronemia, and to prevent or treat diseases or disorders, for which abnormal lipid metabolism is a risk factor, such as cardiovascular diseases.

    ANTI-ANGPTL3 ANTIBODIES AND USES THEREOF
    3.
    发明申请
    ANTI-ANGPTL3 ANTIBODIES AND USES THEREOF 审中-公开

    公开(公告)号：US20190315851A1

    公开(公告)日：2019-10-17

    申请号：US16435032

    申请日：2019-06-07

    Applicant: Regeneron Pharmaceuticals, Inc.

    Inventor： Mark W. SLEEMAN ,  Viktoria GUSAROVA ,  Andrew J. MURPHY

    IPC: C07K16/22 ,  A61K31/455 ,  A61K45/06

    Abstract: A fully human antibody or antigen-binding fragment of a human antibody that specifically binds and inhibits or interferes with at least one activity of human angiopoietin-like protein 3 (hANGPTL3) is provided. The human anti-hANGPTL3 antibodies are useful in treating diseases or disorders associated with ANGPTL3, such as hyperlipidemia, hyperlipoproteinemia and dyslipidemia, including hypertriglyceridemia, hypercholesterolemia, chylomicronemia, and so forth. Furthermore, the anti-hANGPTL3 antibodies can be administered to a subject in need thereof to prevent or treat diseases or disorders, for which abnormal lipid metabolism is a risk factor. Such diseases or disorders include cardiovascular diseases, such as atherosclerosis and coronary artery diseases; acute pancreatitis; nonalcoholic steatohepatitis (NASH); diabetes; obesity; and the like.

    NON-HUMAN ANIMALS THAT MAKE SINGLE DOMAIN BINDING PROTEINS
    4.
    发明申请
    NON-HUMAN ANIMALS THAT MAKE SINGLE DOMAIN BINDING PROTEINS 审中-公开
    制造单一结合蛋白质的非人类动物

    公开(公告)号：US20150289489A1

    公开(公告)日：2015-10-15

    申请号：US14664765

    申请日：2015-03-20

    Applicant: Regeneron Pharmaceuticals, Inc.

    Inventor： Lynn MACDONALD ,  Andrew J. MURPHY ,  Cagan GURER ,  John MCWHIRTER

    IPC: A01K67/027 ,  C07K16/00

    CPC classification number: A01K67/0278 ,  A01K2207/15 ,  A01K2217/072 ,  A01K2217/15 ,  A01K2227/105 ,  A01K2267/01 ,  C07K16/00 ,  C07K2317/515 ,  C07K2317/52 ,  C07K2317/569 ,  C07K2317/64 ,  C12N15/8509

    Abstract: Genetically modified non-human animals and methods and compositions for making and using them are provided, wherein the genetic modification comprises (a) a deletion in an immunoglobulin constant region CH1 gene (optionally a deletion in a hinge region) of a heavy chain constant region gene sequence, and (b) replacement of one or all endogenous VH, DH and JH gene segments with at least one unrearranged light chain variable (VL) gene segment and at least one unrearranged light chain joining (JL) gene segment capable of recombining to form a rearranged light chain variable region (VL/JL) nucleotide sequence operably linked to the heavy chain constant region gene sequence comprising a deletion in the CH1 gene and/or insertion of a genetically engineered single rearranged light chain, wherein the mouse is capable of expressing a functional IgM, single domain antigen binding proteins, e.g., VL-single domain binding proteins, and a genetically engineered rearranged light chain.

    Abstract translation: 提供了遗传修饰的非人动物，以及制备和使用它们的方法和组合物，其中遗传修饰包括（a）重链恒定区的免疫球蛋白恒定区CH1基因（任选地在铰链区的缺失）中的缺失 基因序列，以及（b）用至少一个未稀释的轻链可变（VL）基因片段和至少一个能够重组的未经稀释的轻链连接（JL）基因片段替换一个或所有内源VH，DH和JH基因片段 形成与重链恒定区基因序列可操作地连接的重排轻链可变区（VL / JL）核苷酸序列，所述重链恒定区基因序列包含CH1基因中的缺失和/或遗传工程改造的单重排列轻链的插入，其中小鼠能够 表达功能性IgM，单结构域抗原结合蛋白，例如VL-单结构域结合蛋白和基因工程重排的轻链。

    METHODS FOR TREATING HYPERLIPIDEMIA WITH AN ANGPTL8 INHIBITOR AND AN ANGPTL3 INHIBITOR
    6.
    发明申请
    METHODS FOR TREATING HYPERLIPIDEMIA WITH AN ANGPTL8 INHIBITOR AND AN ANGPTL3 INHIBITOR 有权

    公开(公告)号：US20250066463A1

    公开(公告)日：2025-02-27

    申请号：US18801099

    申请日：2024-08-12

    Applicant: REGENERON PHARMACEUTICALS, INC.

    Inventor： Jesper GROMADA ,  Viktoria GUSAROVA ,  Andrew J. MURPHY

    IPC: C07K16/22 ,  A61K9/00 ,  A61K39/00

    Abstract: The present invention provides methods for treating patients suffering from hyperlipidemia, wherein the patient is non-responsive to, inadequately controlled by, or intolerant to treatment with a standard lipid modifying therapy. The methods of the invention provide for lowering at least one lipid parameter in the patient by administering a therapeutically effective amount of an antibody or antigen-binding fragment thereof that specifically binds to angiopoietin-like protein 8 (ANGPTL8) in combination with a therapeutically effective amount of an antibody that specifically binds to angiopoietin-like protein 3 (ANGPTL3). The combination of an anti-ANGPTL8 antibody with an anti-ANGPTL3 antibody is useful in treating diseases such as hypercholesterolemia, including familial hypercholesterolemia (FH), both heFH and hoFH, as well as hyperlipidemia, hyperlipoproteinemia and dyslipidemia, including hypertriglyceridemia, chylomicronemia, and to prevent or treat diseases or disorders, for which abnormal lipid metabolism is a risk factor, such as cardiovascular diseases.

    DELIVERY OF A GENE-EDITING SYSTEM WITH A SINGLE RETROVIRAL PARTICLE AND METHODS OF GENERATION AND USE
    8.
    发明申请
    DELIVERY OF A GENE-EDITING SYSTEM WITH A SINGLE RETROVIRAL PARTICLE AND METHODS OF GENERATION AND USE 审中-公开

    公开(公告)号：US20200216860A1

    公开(公告)日：2020-07-09

    申请号：US16644411

    申请日：2018-09-05

    Applicant: Regeneron Pharmaceuticals, Inc.

    Inventor： Christos KYRATSOUS ,  Andrew J. MURPHY ,  Cheng WANG

    IPC: C12N15/86 ,  C12N9/22

    Abstract: The invention provides a recombinant RNA molecule comprising (i) a sequence of a gene-editing molecule mRNA, or a sequence of a functional fragment or derivative thereof, and (ii) at least one sequence of a coding or non-coding enrichment RNA, or a sequence of a functional fragment or derivative thereof, wherein the enrichment RNA, or functional fragment or derivative thereof, is capable of enhancing inclusion of the gene-editing molecule mRNA, or functional fragment or derivative thereof, into a retroviral particle. The invention provides a method of producing the retroviral particles of the invention, the method comprising culturing a packaging cell in conditions sufficient for the production of a plurality of retroviral particles.

    GENETICALLY MODIFIED MAJOR HISTOCOMPATIBILITY COMPLEX MICE
    10.
    发明申请
    GENETICALLY MODIFIED MAJOR HISTOCOMPATIBILITY COMPLEX MICE 审中-公开
    遗传修饰主要组织复合体系

    公开(公告)号：US20140245467A1

    公开(公告)日：2014-08-28

    申请号：US14185316

    申请日：2014-02-20

    Applicant: Regeneron Pharmaceuticals, Inc.

    Inventor： Lynn MACDONALD ,  Andrew J. MURPHY ,  Vera VORONINA ,  Cagan GURER

    IPC: A01K67/027

    CPC classification number: A01K67/0278 ,  A01K2207/15 ,  A01K2217/072 ,  A01K2267/03 ,  C07K14/70514 ,  C07K14/70517 ,  C07K14/70539 ,  C12N15/8509

    Abstract: The invention provides genetically modified non-human animals that express chimeric human/non-human MHC I and MHC II polypeptides and/or human or humanized β2 microglobulin polypeptide, as well as embryos, cells, and tissues comprising the same. Also provided are constructs for making said genetically modified animals and methods of making the same. Methods of using the genetically modified animals to study various aspects of human immune system are provided.

    Abstract translation: 本发明提供了表达嵌合人/非人MHC I和MHC II多肽和/或人或人源化＆lt; 2微球蛋白多肽，以及胚胎，细胞和包含其的组织的遗传修饰的非人动物。 还提供了用于制备所述转基因动物的构建体及其制备方法。 提供了使用遗传修饰动物研究人体免疫系统各个方面的方法。

Patent Agency Ranking